Eagle Eye CEO Touts Temperature Screening While Rushing

By John Honovich, Published Nov 02, 2020, 02:47pm EST

Eagle Eye's CEO Dean Drako is celebrating raising $40 million in an SSN interview where he was quoted touting temperature screening while people "walk, or run, by an entrance, and you can measure hundreds of people per minute".

IPVM Image

Drako explained to IPVM that he was "not sure if [he] said run' or 'rush'" emphasizing that Eagle Eye cannot enforce FDA guidelines but do encourage following them.

Executive *******

********** **** *****'* **** the ****** * ***** sense ** **** *********** screening ******* *************** *** ********* *** guidance ***** ****** ***** Eye * *********** ********* against ********* **** ** follow *** ******** *** do *** ******* *** public **** ******** **** temperature ********* ***** ********** when ******** ** ****** are ******* ** ******* by *** ******.

**** ** ******* **** example ** *** *** FDA ***** ** ***** down ** ********** ********* and ***** ***********.

SSN *********

**** ******* **, **** SSN *********, ***** ***'* *** touted *** *********** ******* could '**** ******'* ******** temperatures ** **** ****, or ***, ** ** entrance, *** *** *** measure ******** ** ****** per ******':

IPVM Image

Clarification *** ********* ** ****

***** ***'* *** **** he *** *** **** if ** **** '***' or '****' *** **** he ***** *** ** change *** ***** ** 'rush':

* ** *** **** if * **** "***" or "****". **** * was ******* ***** **** is ******* ******* * door. ** **** **** deployments ** ******** **** Thermal ******* **** **** successfully ******** *** ************ of ****** ******** ******* an ******** ***** *******. We **** **** ******* quite ********* **** ******** are ********* ** *** camera ******* ** *** into ******. ** **** asked **** ** ******* the ***** ** *** "rush" ** "***"

** *** *** **********, Eagle ***'* *** ********** they ****** ******* ***** customers ** ****** **** and **** *******, ********* washing ***** *** ***** manual ************ ** ********* or *******:

*** *** ********** ** this *** *****. *******, we ****** ******* **** on *** ********* - that ** *** *** role. *********** ******** ** have **** ******* ******** that *** ******* ***** numbers ** ****** ** they ****** **** ********* through ****** ** ******** doors. *** ********** *** been **** **** ********* do * ********* ****** of ****** **** ** flagged ** *********** ** anyone **** *** ****** misses. ** *** **** these ******* *** *** foolproof *** *** *** perfect. ******* **** ***** is *** ********* ** perfect. * ****** *********** is *** ********* ** perfect. **** ***, *******, all *****, **** **** their *****.

**** ******* **** *** concern ** **** ** saying ***** ******* "**** read ******’* ******** ************ as **** ****, ** run, ** ** ********, and *** *** ******* hundreds ** ****** *** minute", ***** ***'* ******** endorsement ** **** *** violating ******** ** *********** customers ** ****** ** in **** * *******. Eagle ***'* *** *********:

** ***** ***** ********** or ********** ********* ********* of *** ***********. ** statement *** ********* *** we *** ********* ***** the ******* *******. ** is *** ***** ** an *********** ** ** encouragement. ***, ***** *** be **** **** ** my ********** *** ** have **** **** ********* using ******* *******. ***** is **** ** **** things.

*** ** *** '******** temperature' *******, ***** ***'* CEO ********** **** ********** 3rd ***** ********, ******** on ******* ***** ******* is ****** **** ******** screening:

*** ***** *** ***** VMS **** *** **** temperatures. ** ******* ******* that **** ************. ** you **** **** ** the ******* **** ********* elevated *********** ********* ** so ** ********* **** detection **** * ******* camera. **** **** ** have **** **** ** integrate **** ******** ***********. Cameras **** *** **** the ***** ******* ***** be ******. ** **** support ***** ******* **** customers *** *** *** manufacturers ********* **** **. Eagle *** **** *** have ** ******* ** whether *** ***** ******* is ****** ** ********. We ****** ********* *** support **** *** ******* and ********* *** ** well ** **** ** can.

** **-********** *** ***** able ** ******* *** they *** **** ** what ******* **** *******:

***** *** ******** ******** Temp ********* *******. *** they *** ******** *** used ** ***** *** control ** *** ******* and *********. ** ******** in *** ******* **** observations ** *** **** are ***** **** ** some ** *** *********. We *** ** ******* our ********* *** ******* about ********, *** ** cannot *** ****** *** attempt ** ******* **** they **. ** ** not ******* **** ******** Temperature ********* ******* *** a ******* ** **** they ** *** **** their ************.

**** ********* ** ****** that ***** *** **** sell / **-**** / white *********** (******** ****) *********** screening. ***** *********:

** ***** ******* ** a *********** ** *** dealers. * ***** *** say ** **** * white ***** "******", ** only **** *** ***** label ******* *** ***** body. ** *** **** selling ******* *** ***** been *** *****. **** of *** *********** ** thermal ******* *** ******** with ***** *********' ******* chosen ** *** *******. The ******* ****** **** they **** *** *** they **** ** ****** it. ** ** ***** offer ***** ***** ******* temp ******* ******* ** our *******. ** ********* they *** ********* *** the ************* ********** *** the ***'* ****** *** information.

Eagle *** ** ***

***** ***'* *** ******* his ******** ** *** FDA's *********** ** **** of *** ********:

*** *** *** ******** **** ******** *********** (updated */**/****). ** *** ********* it ******* ** ** "information". **** ** *** title ** ********* ** guidelines. ** **** ******* the "****** ***", ******* it ****** **** *** statement "****** *** ************ instructions" ******** **** **** supersedes ***** "****** ***" information. ********** ** ********* it ** ********. **** before *** *** ********* this *******, *** ** info ** ** *** included ** *** ******** and *** *** ***************. It ** ******** ***** for ***** ******* *******. Our ******** ** *** resellers *** *** *** customers ******* ********** *** FDA ***********. ********* ***** conditions **** **** *** best *** **** ******** results. ** **** ***, however, **** **** ********* will *** **** ***** in ***** **** ** less ***** **********. **** is ********* *** ******** needs ** ******. ** want *** ********* ** be ***** *** ** the ***** *****. ** encourage ********* *** ***** the *** ***********.

******'* "*********** **********" ****** April **** ********* ************** *** ***'* ********* and ****** ** ************ and ******** ************. ** obviously ****** *****.

FDA ***** ** *********

*****'* ******** ********** *** the *** ***** ** crackdown, ****** *** *****, on *** ********* *** deployments.

*** *******, ***** ****:

** ****** **** *** statement "****** *** ************ instructions" ******** **** **** supersedes ***** "****** ***" information.

***** ** *** ******** excerpt**** *** ***:

IPVM Image

** * ****** ** fever ****** *******, *** logic ** ************ ************ trumping ***'* *** ****** use *********** ***** *****. It **** *** ** us. *** ** **** not **** ********** ** regulatory *****, ***** ** is * ******** **** any ************ *** ****** whatever ************ **** ****.

*** ***, **** ** April *** ***, *** not ****** ***** **** ** ***+ new ************ **** ******* ************ algorithms **** **** ** hard *** ***** ** see **** ***** *** setups (****** ******* ** rushing **** **** ** from *** **** ** cold, ***.) **** ********** actual *****.

Thanks ** *****

*********, **** ***** ** not *****. ** ***** a **** **** ** salesmen ******* ***, ******* self-deceptively, ********* ***** ****** systems ** **** **** put ****** ****** ** risk.

*** **** ** ******* good ****, **** * famous ********** ************, ** why *** *** ***** to ***** **** ** market ************ ********* ** enforce ****** *** ****** practices.

Comments (13)

Undisclosed End User #1

11/02/20 07:55pm

** **** ***** ** have ** **** *** attention ** *** *** and ******** **** ** follow ******* **** ***** "Enforcement ******".

Undisclosed Manufacturer #2

11/02/20 10:01pm

***** *** ******* ****** because ******* ******** * little!!! *** ******** **** you ***** **** **** to ****** *** *** to ***** *** ******* then ** *** *** everyone *** ***** ** to ****** *****' *********!!!

John Honovich

IPVM | In reply to Undisclosed Manufacturer #2 | 11/02/20 10:07pm

******* ******** * ******

******** ** **** '***' to '****' **** *** change *** ******* ** it ********* *** **********. And ******** ** '*** ******* ******** ** people *** ******' **** as ****.

*******, * ***** *** bigger ***** ** **** Drako **** ** ******** down *** ********* ** his **********. **'* ***** an ***-****** **** *** a *** ****** *** rationalizes ***** ********.

Undisclosed #3

In reply to John Honovich | 11/02/20 11:05pm

** ******** **** ** Drako's ******** **** *** numerous ********** ** ******** Temperature ********* (** ***).

**** ** *** **** it's ******** *** (******** Skin ***********) *********? ** is ** ****** ** a *** ******* ** try *** ******* *** apparent ********** ** *** ability ** ******* ****** moving ******* (******* ******* or ****** *******) *** at *** **** **** by ****-********* ******** ***** and ******** *********** ********?

Undisclosed Integrator #4

In reply to Undisclosed #3 | 11/02/20 05:20pm

****** ** *** ******** on *** *** ** AC. *'* ** **** MPDDI.

Undisclosed #3

In reply to Undisclosed Integrator #4 | 11/03/20 06:14am

*******, ***** ******** **** by ***** *********"*** **********" ********* ** pretend **** ** *** anything ** ** **** - *** ***** ***** a ******* ** - his ***************"*********** ********" ********.

"*********** ******** ** **** seen ******* ******** **** are ******* ***** ******* of ****** ** **** stream **** ********* ******* double ** ******** *****.Our ********** *** **** **** **** ********* ** * ********* ****** ** ****** **** ** ******* ** *********** ** ****** **** *** ****** ******."

**** ** *********.

*** ***** **** *** exact **** ***** ** almost ***** * ******** paragraph ** ** ****** in *****....

*****, **** * ******* statement ** **** ***** sentence *** **** ****** with **** ********** ********* that *** ******* ** do **** *** ******** sentence, ********** ** ******** the ***** ********.

John Honovich

IPVM | In reply to Undisclosed #3 | 11/03/20 01:05pm

*********** ******** ** **** seen ******* ******** **** are ******* ***** ******* of ****** ** **** stream **** ********* ******* double ** ******** *****

**** ** ***** *** having ****** ***** ** such * *********** ******. A ****** *** ** deployed **** ***** ****** streaming **** * ******** that ******* ******** ******* temperature ********. *******, **** does *** **** *** system ** '********' ** will ******** ****** *** rare ****** *** **** have * ********** ******** temperature. **** ** *** issue ** **** **** in *** *******.

Undisclosed Integrator #5

11/10/20 03:17pm

** ** ********** ****** all *** ****** *********** are "*** ****". **** are ***** ********* ****** because ** ** ********* to **** *** *** doing*********, ** ******* ** doing *******. **** *** camera ****** *********** *** an ********** ***** ** money *** ********* **** are ****** ** "**-****" or ******* ********** **** a ********* *******.

*** **** ********* **** hire ********* *** **** employees **** **** **** trained ** ******** ****** the ****** *** ******* it ** *** ****** prescribed ** *** ************? How **** ********* **** provide * ****** ******** space *** ********** ** the ******, ** ******* to ****** ** *** it **** ***** ******** lobby, ********, ***.? *** many ********* **** **** and ***** ********* ** operate ** ** *** manner ******* ** *** manufacturer? *** **** ********* will ************ **** *** camera *** ***** **** in *** **-*********** *** re-certification ** ******** ** the ************?

** **** *** **** the ******** **** ** IPVM **** **** **** customers **** **** ********* of ***** ******* *** are ****** ******** ***** and ******* ***** ******** purchasing ******** - ********** of *** ********** ** the ********** *******. ** fact ** ********* *** companies ******* *** "*********" that **** ** ******** installation ******** - **** will ** ****-********* ** the ******** ** ******** through * ********** **** use *** ********, ******* cabling, ***. *** ********* will ***** *********** **?

**********, ****'* ********** ******* how *** ******* **** actually ** **** ** most *********, *** *** way **** ****** ** used ** ******** ****** an ******** ***********. *** has ** ****** *** the ********** *****'* *** FDA *********** ** ***** standards ** ********* - especially **** *** ********* of ******** *********** *** deceptive ********* **** *** been ********* ***** *** one. **** *** **** a **** *** ** testing *** ******* ******* of ***** *****. *** would ***** ******** ** the ******* ***** ** stimulated **** * ******* of *** ******** ** just **** **** *****.

************* *** ******** ** people ******** ** *****-** are ************. **** **** sail ***** **** ***** cameras *** ****** ***** co-workers *** ****** **** know ***** ***** ********* actually **** ****.

John Honovich

IPVM | In reply to Undisclosed Integrator #5 | 11/10/20 10:24am

*** *** ** ****** how *** ********** *****'* see *** *********** ** these ********* ** *********

* ***'* ******* ****'* the *********** **********. *** government ** ******* **** a ***** ** *********** issues (**** **** *********, cures, ***.) *** ******* through ****. * ** believe ****, ***** ****, the ********** **** ** something ****.

Undisclosed Integrator #5

In reply to John Honovich | 11/10/20 05:19pm

** *** ***** ** disagree. **** *** *** mission *********:

"*** **** ***** * significant **** ** *** Nation's **************** **********. *** fulfills **** ************** ** ensuring *** ******** ** the **** ****** *** by ********* *********** ** medical ******** ** ******* to ********** *** ********* emerging ****** ****** *******."

**** *** *** ******* to ***** ** *** declare ***** ******* "******* equipment" **** **** ******* responsibility *** *************************. ** ****** *** being *** ** ******* that * ********** ** being ******** *** ***** safety / ******* ** deserves ********* ****** **** there *** ******** **********.

** **** *** *** dollars *** ***** ***** on ***** ******* **** are ***** ** ** ineffective. *** **** **** do ** **** *** FDA ** ******* *** law **** ***** ******* are ***** ******** ** schools *** *** ** dubious ********? **** ***** systems ******** ** ******* homes / ******** ****** facilities - ***** **** of *** ******* **** people ****? **** ** something **** ****** ******.

*** ********* ******* ** the *** ** *********** swamped **** ****. *** skillset ** * ****** evaluating *** ************* ** a ******* ** ***** likely **** ********* **** the ******** ** *** person ******** ** ******** an ********** *********** ********* device. *'* **** ***** are ****** *** ***** be ******** ** ********* like **** ** * higher ******** *** *** immediate ****** ** *** country. **** ******* **** people *** *** ********** the ******* ** ********* or *** - *********** is *** **** ******* in ********.

John Honovich

IPVM | In reply to Undisclosed Integrator #5 | 11/10/20 10:59pm

** *** ***** ** disagree.

* ***'* ************ ********, certainly *** ** *********. My ***** ** **** that * ***'* ***** the *** *****'* ***** this ** ********* ** much ** **** ***** wave *****+ *** ********** ********* *** *** FDA ** *********** ******* to.

***** *** *** **** never ** ********, ***** they *** ********* ****** in *** ****** ****. Geez, ******* ***** *** *** FDA ** ********* ** this.

*'* **** ***** *** others *** ***** ** assigned ** ********* **** this ** * ****** priority *** *** ********* safety ** *** *******.

* ** ***** **** have **** ******. *** question ** ***** **** are ** ** ***** evaluations ** ****.

Undisclosed Manufacturer #6

11/10/20 07:56pm

***** *******! **** * see * ***** **** Dean * **** **** he ** *** ********** at *** ******. “**** see *** ******* **** and **** *** – half *****.” ** ** a **** **** *********** and * **** ***********. I ******** ******* ** an ************ **** * global *********** ***** ******** lanes ** ** *** approved ****** ** ******* 400 ****** ** ***** 20 *******. ** **** a *** ** ****, but * ***** ** are **** **** **** of ******** **** ***** more***************** ** ********* *********************** **** *** ***.

**** ** ***** ** COVID-19 *** ****** ******** to **** * *** with * ******* ** large *** ***** *** were ******* ** ******** solutions ** ****** ******** as ******** ** *** subject ******. *** *** universal ***** **** *** spoke ***** *** ************* and ********** ********* ********** with *** *******. * spend * ***** ********** the ***** **** * Global ******** ******** **** a ******* *** ********* company **** ******** *** heard **. ** *** amazing *** **** **** had ************ ** ********* 45 ****. *** ******* issue ** *** *** the ********* ********** **** the *******. *** ******* I **** **** *****’* remark ** ******** *** idea **** ****** ******* or ******* ******* *** testing **** ** **. If ** ******** ****** “rushes” ******* *** ******* area, *** **** ** it ***** ** **** to ***** **** ****** down *** *** **** innocent ****** **** **** in ******* ****? **** is *** ******** **** going ** **? *** whole **** **** ** to ****** * ***** point ***** ****** **** an ******** *********** *** kept *** ** *** facility. **** ****** ******** Manager *** ***** ** move *** ******* **** outside ** *** ******** to **** *** ******** people **** ******** *** building ********** *** ************* others. ** ***** ** these ***** ******** ****’* remarks ****** **** ********* to *** ***** ** a ******** ********** *** public ******. ** ** imperative **** *** *** cracks **** ** **** sort ** **************.

John Honovich

IPVM | In reply to Undisclosed Manufacturer #6 | 11/10/20 11:03pm

* *** * ***** from **** * **** like ** ** *** ringleader ** *** ******.

***, * ***'* *** Dean ** * ********** at * ****** *** I ** ********* ***** his ******* ** **** things. **** *** **********, I ***** **** ******* he ***** **** * more ******** *********** *********** on ******...

*** ******* ***** ** had *** *** ********* associated **** *** *******. The ******* * **** with *****’* ****** ** creating *** **** **** people ******* ** ******* through *** ******* **** is **.

****. **** ***** ** reflecting ** ****** ********* what **** ***** **, convenience *** ****** ********. Just **** ** *** if *** **** * fever ** **** *** you. *** ******* ** that ** ** *** grounded ** ********** ******* and **** ***** **** problems **** ****.

Read this IPVM report for free.

This article is part of IPVM's 6,731 reports, 908 tests and is only available to members. To get a one-time preview of our work, enter your work email to access the full article.

Already a member? Login here | Join now
Loading Related Reports